
PT-141 works through your brain's desire pathways to restore libido and arousal, unlike medications that only address blood flow. A fundamentally different approach to sexual wellness.
Low libido, decreased sexual desire, reduced arousal, and patients whose sexual wellness has declined and who haven't found relief from conventional treatments. PT-141 works for both men and women by targeting the neurological root of desire rather than just the physical mechanics.
PT-141 is a synthetic analog of alpha-MSH that activates melanocortin receptors (MC3R and MC4R) in the hypothalamus. Unlike PDE-5 inhibitors that work through blood flow, PT-141 enhances libido at the neurological level by modulating the brain circuits involved in sexual desire, arousal, and reward. Treatment is subcutaneous and prescribed under clinical supervision.
Sexual wellness is a clinical conversation, and we treat it that way. Your provider discusses your history, goals, and any relevant health factors before prescribing. 503A pharmacy sourced, clinician-monitored. Available at our Lincoln Park clinic or via telehealth across Illinois.

We're here to answer your questions and provide the best services for your needs. Schedule a consultation to learn how to reach your aesthetic goals.
Libido Enhancement at Better Med Spa centers on PT‑141 (bremelanotide), a melanocortin receptor agonist that acts in the hypothalamus to enhance sexual desire and arousal rather than just blood flow. Given as a low‑dose subcutaneous injection ahead of anticipated intimacy, this non‑FDA–approved protocol is offered under informed consent and tailored around each client’s health, triggers, and relationship goals.
PT‑141 is a synthetic analog of alpha‑MSH that activates melanocortin receptors (especially MC3R and MC4R) in the hypothalamus, modulating neural circuits involved in sexual desire, arousal, and reward. Unlike PDE‑5 inhibitors, which act primarily via peripheral vasodilation, PT‑141 works centrally, enhancing libido independent of direct vascular effects and often improving both spontaneous desire and responsiveness to erotic cues. In clinical trials, on‑demand PT‑141 has improved distressing low desire (HSDD) in premenopausal women and increased erectile responses in men, with onset typically within about 45 minutes and effects lasting several hours.
Our PT-141 peptide is designed to target:
PT-141 is believed to help with: